Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,854 GBX | +2.26% | +3.63% | +3.63% |
Apr. 25 | Hikma Pharmaceuticals backs outlook after making strong start to 2024 | AN |
Apr. 25 | Hikma Pharmaceuticals Affirms FY24 Guidance | MT |
Summary
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's high margin levels account for strong profits.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+3.63% | 5B | B+ | ||
+24.17% | 562B | B | ||
-6.33% | 358B | C+ | ||
+19.90% | 322B | B- | ||
+7.95% | 297B | C+ | ||
+13.45% | 219B | B+ | ||
+6.04% | 199B | B- | ||
-10.51% | 196B | A+ | ||
-12.26% | 149B | C+ | ||
-6.47% | 146B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- HIK Stock
- Ratings Hikma Pharmaceuticals PLC